Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Global Cord Blood (NYSE:CO) in a research note issued to investors on Saturday morning. The firm issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

Global Cord Blood stock opened at $1.25 on Friday. Global Cord Blood has a 12 month low of $2.03 and a 12 month high of $5.50. The company’s fifty day simple moving average is $1.25 and its 200-day simple moving average is $1.36. The stock has a market cap of $151.94 million, a P/E ratio of 1.95 and a beta of 0.16.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.